User login
Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.
Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.
Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.
Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.
Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061
Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.
Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.
Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.
Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.
Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061
Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.
Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.
Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.
Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.
Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061